CrystalGenomics and Standigm, Agree to Collaborate on Utilizing Artificial Intelligence and Structure-Based Drug Design Technologies in Drug R&D

Updated:

Seoul, Korea, South, June 01, 2017 –(PR.com)– CrystalGenomics, Inc. (KOSDAQ: 083790) and Standigm, Inc., today announced the collaborative partnership to apply Artificial Intelligence (AI) to the research and development of novel drugs.

Read more

Categories: Press